Kardigan, Inc. (NasdaqGM: KARD)
Health Care · Pharmaceuticals · US
$20.69
-1.10% today · -4.9% 1Y
Kardigan, Inc. (NasdaqGM: KARD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.96B and employs 241 people.
Over the last twelve months the share price has lost 4.9%, trading between 16.25 and 27.00.
KARD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.96B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -17.13
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $27.00
- 52-week low
- $16.25
- Avg volume (3M)
- —
- Shares outstanding
- 93.50M
- Employees
- 241
- Next earnings
- —
About Kardigan, Inc.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
- ISIN
- US4859251013
- Founded
- 2023
- Listed since
- Jun 18, 2026
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,199.25 | -2.79% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.42 | -1.00% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $154.02 | -1.55% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.40 | -0.60% |
Figures last refreshed Aug 18, 2026.